Loading...
Carna Biosciences, Inc.
4572.T•JPX
Healthcare
Biotechnology
¥300.00
¥-6.00(-1.96%)
Carna Biosciences, Inc. (4572.T) Financial Performance & Income Statement Overview
Review Carna Biosciences, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-60.87%
↓ 60.87%
Operating Income Growth
-85.87%
↓ 85.87%
Net Income Growth
-88.97%
↓ 88.97%
Operating Cash Flow Growth
18.04%
↑ 18.04%
Operating Margin
-359.91%
↓ 359.91%
Gross Margin
71.96%
↑ 71.96%
Net Profit Margin
-380.22%
↓ 380.22%
ROE
-88.49%
↓ 88.49%
ROIC
-106.71%
↓ 106.71%
Carna Biosciences, Inc. (4572.T) Income Statement & Financial Overview
Review Carna Biosciences, Inc.'s (4572.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $149.02M | $172.22M | $134.77M | $180.87M |
| Cost of Revenue | $47.38M | $41.17M | $35.96M | $46.67M |
| Gross Profit | $101.64M | $131.05M | $98.81M | $134.20M |
| Gross Profit Ratio | $0.68 | $0.76 | $0.73 | $0.74 |
| R&D Expenses | $0.00 | $0.00 | $615.03M | $377.42M |
| SG&A Expenses | $599.74M | $614.06M | $162.55M | $173.02M |
| Operating Expenses | $599.74M | $614.06M | $777.57M | $550.44M |
| Total Costs & Expenses | $647.11M | $655.23M | $813.53M | $597.11M |
| Interest Income | $0.00 | $0.00 | $26000.00 | $2.52M |
| Interest Expense | $0.00 | $0.00 | $800000.00 | $926000.00 |
| Depreciation & Amortization | $7.81M | $8.75M | -$6.82M | $7.58M |
| EBITDA | -$490.28M | -$474.26M | -$685.59M | -$388.60M |
| EBITDA Ratio | -$3.29 | -$2.75 | -$5.09 | -$2.15 |
| Operating Income | -$498.10M | -$483.009M | -$678.76M | -$416.24M |
| Operating Income Ratio | -$3.34 | -$2.80 | -$5.04 | -$2.30 |
| Other Income/Expenses (Net) | -$91.18M | -$9.69M | -$15.52M | $19.13M |
| Income Before Tax | -$589.28M | -$492.70M | -$694.28M | -$397.11M |
| Income Before Tax Ratio | -$3.95 | -$2.86 | -$5.15 | -$2.20 |
| Income Tax Expense | $713000.00 | $1.89M | $950000.00 | $1.78M |
| Net Income | -$589.99M | -$494.58M | -$695.23M | -$398.89M |
| Net Income Ratio | -$3.96 | -$2.87 | -$5.16 | -$2.21 |
| EPS | -$31.07 | -$27.40 | -$39.84 | -$23.27 |
| Diluted EPS | -$31.07 | -$27.41 | -$39.84 | -$23.27 |
| Weighted Avg Shares Outstanding | $18.99M | $18.05M | $17.45M | $17.14M |
| Weighted Avg Shares Outstanding (Diluted) | $18.99M | $18.05M | $17.45M | $17.14M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan